NY-CURIA
22.12.2021 15:02:05 CET | Business Wire | Press release
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today unveiled its messenger RNA (mRNA) solution, which includes discovery, process development and mRNA drug substance production, through large-scale lipid manufacturing, lipid nanoparticle (LNP) formulation and development for full-scale sterile fill-finish services.
Curia’s mRNA solution is designed to streamline the development and delivery of mRNA-based products, which span various therapeutic areas including cancer, heart disease and chronic illnesses in addition to its current application in vaccines.
“The extraordinary impact of mRNA on the COVID-19 pandemic demonstrates its potential to save and improve lives,” said Curia Chairman and Chief Executive Officer John Ratliff. “mRNA has the potential to play a pivotal role in the next frontier of treatments for unmet medical needs. Curia’s capabilities enable customers to accelerate the discovery and development of next-generation mRNA therapeutics from curiosity to cure.”
Curia’s team brings a powerful combination of proven expertise, speed and reliability across research, process development and manufacturing to accelerate mRNA product development timelines:
Discovery
Curia’s mRNA solution combines expertise and a proven track record of success in key scientific disciplines including molecular biology, protein production and analysis, enzymes, nucleosides and lipids. The platform’s ability to provide high-quality constructs through in-house research and analysis capabilities enables accelerated timelines for delivery.
Development of Lipid and RNA Drug Substance Through Manufacturing
Curia’s end-to-end capabilities extend from production of plasmid DNA and manufacturing of enzymes and nucleosides at gram-to-kilogram scale, to drug substance development through first-in-human clinical supply manufacturing. Its five sites in California and Massachusetts provide reliable plasmid production for “traditional” and self-amplifying mRNA drug substance. First-in-human clinical-scale cGMP manufacturing is supplemented by in-house analytical capabilities for product testing and release.
Curia has a proven track record in the rapid development of numerous specialized lipids for mRNA applications and the ability to manufacture lipids to metric-ton scale in accordance with cGMP. Curia’s scientists have expertise in coupling synthesis with highly effective separations and purifications of APIs and functional excipients.
Development of Lipid Nanoparticle Formulation, Testing and Sterile Fill-Finish Through Manufacturing
Curia’s mRNA solution includes complex formulation capabilities and experience in liposome and lipid nanoparticles led by its expert scientists. Curia completes its end-to-end offering with clinical and commercial aseptic sterile fill-finish capability and capacity. Its facilities provide process development and first-in-human clinical manufacturing through to full commercial manufacturing of mRNA injectable dosage products in accordance with cGMP.
About Curia
Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s 3,700 employees at 29 locations across the U.S., Europe and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211222005047/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hitachi Report Examines Readiness for Physical AI in Industrial Companies22.10.2026 14:00:00 CEST | Press release
AI adoption progress, trends, and emerging priorities suggest opportunities and challenges for physical AI acceleration Hitachi, Ltd. (TSE:6501, "Hitachi") announced the release of its physical AI survey-based research report, Beyond the Pilot: Industry’s Physical AI Progression. The company surveyed over 200 global decision-makers from organizations operating in mission-critical industrial sectors including energy, manufacturing, transportation and logistics. The report explores how businesses today adopt AI in industrial use-cases, where they see the greatest value, and what it will take to scale toward physical AI deployments. Readers will gain practical insights on how to accelerate AI adoption while improving competitiveness, productivity, and long-term business performance. After successfully transforming knowledge work, AI is now entering the physical systems that form society’s backbone: energy, industrial, and mobility infrastructure, to name a few. Given these systems’ reliab
Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License22.10.2026 14:00:00 CEST | Press release
Expanded healthcare platform would bring together patient-controlled data tokenization, biometric medication verification, and automated delivery technologies Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced that it has entered into a non-binding letter of intent (“LOI”) to acquire a 19.9% equity interest in DataMEDS AI, Inc. (NASDAQ: MEDS) (“DataMEDS”) in consideration of an expansion of its existing technology license with DataMEDS. The proposed transaction is subject to completion of due diligence and negotiation of definitive agreements and will be subject to customary closing conditions for a transaction of this nature. The proposed transaction is structured to provide Datavault AI with the opportunity to obtain an equity interest in DataMEDS while preserving ownership of its underlying intellectual property.
Megaport Expands AWS Connectivity With AWS Interconnect to Simplify How Customers Connect Their Infrastructure22.10.2026 14:00:00 CEST | Press release
As one of a select group of providers, Megaport adds AWS Interconnect to its complete suite of AWS connectivity options. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced support for AWS Interconnect, a new managed connection model from Amazon Web Services (AWS) designed to simplify how businesses connect their infrastructure to AWS. AWS Interconnect from Megaport gives enterprises and AI infrastructure providers an automated connectivity option as their requirements grow beyond traditional AWS Hosted Connections. MACsec encryption and four redundant links across two sites will be included as part of the service at general availability, with customers able to select connection speeds from 1 Gbps to 100 Gbps. Customers can start an order for AWS Interconnect - last mile from either the Megaport Portal or AWS Management Console and complete it from the other. AWS and Megaport then automate the underlying network configuration, i
Scientist.com Launches Agentic AI Platform for Research Procurement22.10.2026 13:55:00 CEST | Press release
Scientist.com connects AI-assisted experimental design to real-world laboratory execution through an established, enterprise-ready supplier network Scientist.com, the leading R&D orchestration platform and marketplace, today announced new agentic AI capabilities that enable scientists to move directly from experimental protocols to qualified laboratory providers and purchase orders. The platform uses AI agents to identify required services, match suitable laboratories, compare proposals, and manage purchasing through existing enterprise procurement workflows. Through Model Context Protocol (MCP), Scientist.com enables external AI assistants, such as Claude, to discover suppliers and initiate research procurement workflows directly. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022796429/en/ Scientist.com uses AI agents to identify platform users' required research services, match suitable laboratories, compare proposals,
NIQ Expands ConnectAI Charter Program with Mars Snacking22.10.2026 12:45:00 CEST | Press release
Mars joins a growing group of global companies working with NIQ forward-deployed engineers to bring proprietary consumer and market intelligence into enterprise AI workflows NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced Mars as a new ConnectAI Charter client, expanding the program’s growing roster of global companies working with NIQ to build the intelligence foundation for amplifying enterprise AI workflows. Through the ConnectAI Charter Program, NIQ forward-deployed engineers and data scientists are working with Mars to embed NIQ intelligence in the expansion of AI-enabled workflows across its business. The engagement focuses on connecting NIQ data, models, and business context with Mars’ AI ecosystem to help reduce the distance between data and decision-making. Together, they are tackling use cases like conversational analytics and harmonized product data to lay the foundation for future use cases. “As we expand the use of AI across our business, we
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom